Remove Cardiology Remove Genetics Remove Research
article thumbnail

Integrating Bioanalytical Automation, Biomarkers, Pharmacogenomics, & Cost-Effective Strategies

Worldwide Clinical Trials

By integrating biomarker analysis into clinical trials, researchers can reduce costs, minimize trial durations, and improve the likelihood of delivering innovative therapies to patients more rapidly and effectively. Moreover, they facilitate regulatory approvals by providing robust, evidence-based data that aligns with stringent requirements.

article thumbnail

How Phosphorus’ GeneCompass Preventative Genetic Test Can Help People Manage Their Health

XTalks

Phosphorus, a leading preventative genomics company, has developed the first comprehensive preventative genetic test for consumers. The test is called GeneCompass and features medical-grade technology to provide a holistic assessment of genetic health and wellness. The Phosphorus GeneCompass test has a list price of $249.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Researchers release analysis of largest, most diverse genetic data set

Scienmag

Data demonstrates new increased diversity in genetic studies and provides new insights into population-specific diseases Researchers at the University of Maryland School of Medicine (UMSOM) and their colleagues published a new analysis today in the journal Nature from genetic sequencing data of more than 53,000 individuals, primarily from minority (..)

article thumbnail

People with genetic predisposition to obesity may have lower risk of cardiovascular disease

Medical Xpress

The risk of developing cardiovascular disease is lower in people with obesity who have a genetic predisposition for high BMI than people with obesity influenced mainly by environmental factors such as lifestyle, researchers from Karolinska Institutet report in eClinicalMedicine.

article thumbnail

Lilly’s Lepodisiran Achieves Over 90% Reduction in Heart Disease Marker in Phase II Trial

XTalks

Eli Lilly shared new Phase II trial data showing that its experimental siRNA therapy, lepodisiran, leads to reductions in levels of lipoprotein(a) (Lp(a)) a genetically inherited risk factor for heart disease in adults with elevated levels of the marker. High Lp(a) levels can double or even triple the risk of a heart attack.

Trials 59
article thumbnail

New genetic clues point to new treatments for ‘silent’ stroke

Scienmag

Decade-long search uncovers genes responsible for lacunar strokes, a major cause of vascular dementia Scientists have identified new genetic clues in people who’ve had small and often apparently ‘silent’ strokes that are difficult to treat and a major cause of vascular dementia, according to research funded by the British Heart Foundation (..)

article thumbnail

New research digs into the genetic drivers of heart failure, with an eye to precision treatments

STAT News

When coronary arteries are blocked, starving the heart of blood, there are good medications and treatments to deploy, from statins to stents. Not so for heart failure, the leading factor involved in heart disease, the top cause of death worldwide. “It’s what’s on death certificates,” said cardiologist Christine Seidman.